A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis.

Trial Profile

A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Natalizumab (Primary) ; Glatiramer acetate; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SURPASS
  • Sponsors Biogen
  • Most Recent Events

    • 10 Mar 2012 This trial has been recruitng in Sweden and Portugal as reported by European Clinical Trials Database record.
    • 27 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top